Skip to main content
OpenTrials
Completed

NCT Number: NCT04865640

Clinical Validation Study for Noninvasive Cardiopulmonary Management Device

The ADI At-Home CPM (Cardiopulmonary Management) System is a non-invasive device that measures and trends a variety of biological parameters.

This study will be conducted as a prospective non-randomized study with two study arms/cohorts - one of healthy adult patients, one of pathologic patients who fit into the intended use population of the CPM System.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiopulmonary Disease Cardiovascular Diseases Heart Diseases Pulmonary Heart Disease

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mayo Clinic Hospital

Rochester, Minnesota, 55905-0001, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

I. Healthy Cohort:

  • Adults over the age of 18 and who are willing and able to give informed consent.
  • Willing to participate in all activities related to this study, including trimming chest hair and wearing a reference device and the CPM wearable device.
  • Volunteers of any race, any gender
  • Range of physiques
  • Healthy

II. Pathologic Cohort

  • Adults over the age of 21 and who are willing and able to give informed consent
  • Willing to participate in all activities related to this study, including wearing a capnography device, thoracic impedance reference device, and the CPM wearable device.
  • Those who:
  • Are taking diuretic medications
  • Are living with heart failure
  • Have chronic obstructive pulmonary disorder (COPD)
  • Are recovering from a coronary-artery disease-related event.
  • Volunteers of any race, any gender-Range of physiques.

Exclusion criteria

I. Healthy Cohort

  • Injury or skin disturbance in the area of the test device
  • Pregnant
  • Currently smokes cigarettes
  • Has known respiratory conditions such as:
  • Flu
  • Pneumonia/bronchitis
  • Shortness of breath/respiratory distress
  • Respiratory or lung surgery
  • Emphysema, COPD, lung disease
  • Has self-reported heart or cardiovascular conditions such as chest pain, AFib, CHF, cardiomyopathy, or other conditions that could interfere with cardiopulmonary function
  • Has other self-reported health conditions that could interfere with the breathing patterns and exercises detailed in the protocol (including wearing a capnography mask)

II. Pathologic Cohort:

  • Under the age of 21
  • Cognitive or physical impairment sufficient enough to interfere with informed consent or successful completion of the protocol.
  • Injury or skin disturbance in the area of the test device.
  • Pregnant.
  • Have life-threatening arrhythmias which require hospital admission and constant monitoring.
  • Has other self-reported health conditions that could interfere with wearing a capnography mask.

Treatment and study plan

Noninterventional and noninvasive

Diagnostic Test

The ADI At-Home CPM (Cardiopulmonary Management) System is intended for adults undergoing monitoring for cardiopulmonary conditions under the direction of a licensed medical professional to measure, record, and periodically transmit physiological data.

Primary outcomes

  1. Correlation Coefficient for Accuracy of Test Device vs Reference Device

    Time frame: Device reading (3 minutes)

    Correlation Coefficient for Respiration Rate accuracy (test device vs reference device).

  2. Root Mean Square Error Accuracy Between CPM and Reference Device for Respiration Rate

    Time frame: Device reading (3 minutes)

  3. Correlation Coefficient Between Reference Tidal Volume (TV) and Test Device Relative Tidal Volume (rTV)

    Time frame: Device reading (3 minutes)

    Accuracy of CPM System calculated rTV (relative Tidal Volume) as compared to reference device calculated TV (Tidal Volume)

  4. Standard Deviation of Thoracic Impedance

    Time frame: device reading (3 minutes)

    Analyses were performed to quantify replication variability. The analysis used Mixed models for repeated measures (MMRM) to obtain the variance component estimates controlling for changes in true status as measured by the bioimpedance reference. The variance components include replication variance within application with three measurements per application (i.e., short-term variance) and application variance with three applications, including an application one hour later (longer-term variance). The model also includes subject to subject variance (adjusted for changes in the bioimpedance reference). Variability among applications is partially explained by changes in bioimpedance reference. Total variance is partitioned into measurement variance, application variance, and subject variance.

  5. Magnitude of Drift for Thoracic Impedance

    Time frame: Device reading (3 minutes)

    The magnitude of drift was evaluated by comparing the magnitude of this longer-term variance to the short term (replication) variance in relative term and comparing the absolute incremental contribution of the longer-term standard deviation to 6 ohms. If adding application variance (controlling for change in bioimpedance reference) does not appreciably increase the total nonsubject variance, no appreciable drift across will have been demonstrated.

Secondary outcomes

  1. ECG Heart Rate Confirmation

    Time frame: Device measurement (3 minutes)

    Confirm that ECG characteristics align with those from bench results using a simulator

  2. Skin Temperature Confirmation.

    Time frame: Baseline

    Confirm that ECG characteristics align with those from bench results using a simulator

  3. ECG Confirmation for Abnormal Rhythms

    Time frame: Device measurement (3 minutes)

    Comparing device ECG Abnormal Rhythm Flags raised by CPM system to cardiologist atrial fibrillation annotation of device ECG strips (3 strips per participant). Counts determine total number of ECG strips flagged with abnormalities if the CPM device or cardiologist annotated atrial fibrillation.

  4. ECG QRS, QT and QTc Confirmation

    Time frame: device reading (3 minutes)

    Confirm that ECG characteristics align with those from bench results using a simulator

Sponsors and collaborators

Lead sponsor

Analog Device, Inc.

Other

Collaborators

  • MCRA

Registry information

Official study title

Clinical Validation Study for Noninvasive Cardiopulmonary Management Device.

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Apr 29, 2021
Registry last updated
Aug 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.